# Prelude Therapeutics Inks Trial Agreement With Lilly for Breast Cancer Study

- URL: https://stocks.freetheai.org/news/prelude-therapeutics-inks-trial-agreement-with-lilly-for-breast-cancer-study-a85cd5
- Published: 2026-10-13T11:01:00Z
- Category: company_news; sentiment: mixed; impact: low
- Symbols: [NASDAQ:PRLD](https://stocks.freetheai.org/symbols/NASDAQ-PRLD)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Prelude Therapeutics, Inc. (PRLD) has entered into a clinical trial collaboration and supply agreement with Eli Lilly to evaluate its drug candidate PRT13722 in patients with HR+/HER2- breast cancer. Under the agreement, the trial will test PRT13722 alongside abemaciclib and imlunestrant. The U.S. Food and Drug Administration has cleared the Investigational New Drug application for the asset.

The agreement secures drug supply for the planned studies while allowing Prelude Therapeutics to retain full global rights to PRT13722. Shares of Prelude Therapeutics fell 3.86% to $3.74 following the news.

Patient enrollment for the Phase 1 trial is expected to start in the fourth quarter of 2026. The study will initial evaluate PRT13722 as a monotherapy before progressing to combination cohorts to evaluate safety and preliminary efficacy signals.

## Key points

- Prelude Therapeutics signed a trial-supply collaboration with Eli Lilly for its drug candidate PRT13722.
- The FDA cleared the Investigational New Drug application for PRT13722.
- Phase 1 clinical trial enrollment is scheduled to begin in the fourth quarter of 2026.
- The study will test combinations with abemaciclib and imlunestrant in HR+/HER2- breast cancer.
- Prelude Therapeutics retains all global rights to the PRT13722 asset.

## Questions and answers

### What is the agreement between Prelude Therapeutics and Eli Lilly?

Prelude Therapeutics signed a clinical trial collaboration and supply deal with Eli Lilly to evaluate PRT13722 in combination with abemaciclib and imlunestrant for treating HR+/HER2- breast cancer.

### When will the Phase 1 trial for PRT13722 begin?

Patient enrollment for the Phase 1 trial is scheduled to begin in the fourth quarter of 2026 following FDA clearance of the Investigational New Drug application.

### Does Prelude Therapeutics retain rights to PRT13722?

Yes, Prelude Therapeutics retains full global rights to PRT13722 under the terms of the agreement.